Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01118221 |
Recruitment Status
:
Completed
First Posted
: May 6, 2010
Results First Posted
: January 16, 2015
Last Update Posted
: March 4, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The incidence and prevalence of IPF increase exponentially with age, and IPF occurs more often in older males. Cigarette smoking and environmental dust exposures are known risk factors for developing IPF. For example, the recently deployed military population, as it ages, is at especially increased risk of IPF. No effective therapies exist, although lung transplantation is used to extend survival of selected patients.
Defining specific therapy to improve exercise tolerance and dyspnea in IPF patients is thus an urgent priority of veteran-oriented research programs.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Idiopathic Pulmonary Fibrosis | Behavioral: pulmonary rehabilitation | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 25 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Rehabilitation of IPF Patients: Effects of Exercise and Oxidant Stress |
Study Start Date : | October 2010 |
Actual Primary Completion Date : | September 2013 |
Actual Study Completion Date : | September 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm 1
enroll in pulmonary rehabilitation program
|
Behavioral: pulmonary rehabilitation
structured exercise program
|
No Intervention: Arm 2
no structured exercise
|
- 6 Minute Walk Distance [ Time Frame: The 6-MWD will be measured at 0 and 3 months. ]Change in 6 Minute Walk Distance from Baseline to 3 Months
- Systemic Markers of Oxidant Stress [ Time Frame: Markers of oxidant stress will be measured in all subjects before randomization after exercise testing at 0 months. ]Plasma F2-isoprostanes measured in all subjects before and after exercise testing at baseline.
- Maximum Oxygen Uptake [ Time Frame: Maximum O2 uptake will be measured at 0 and 3 months. ]Change in 6 peak O2 uptake from Baseline to 3 Months

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 80 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinical presentation consistent with IPF with onset between three months and 48 months prior to screening.
- Diagnosis made by high-resolution computed tomographic scan showing highly probable IPF.
- Absence of severe pulmonary hypertension (i.e., PAsys must be less than 55 mm Hg, based on echocardiography) and absence of decompensated right heart failure (NYHA class I or II acceptable).
- Age 40 through 80, inclusive.
- Abnormal pulmonary function tests (FVC 40-90% predicted or DLCO 30-90% predicted or impaired gas exchange with rest or exercise).
- Six-minute walk distance 150 m and 500 m.
- Worsening as demonstrated by any one of the following within the past year: > 10% decrease in percent predicted forced vital capacity or worsening dyspnea at rest or upon exertion, based on history.
- Ability to understand and sign a written informed consent form and comply with the requirements of the study.
- Absence of clinical features suggesting infection, neoplasm, sarcoidosis or collagen-vascular disease.
Exclusion Criteria:
- Echocardiographic evidence of severe pulmonary hypertension (PAsys>55 mm Hg, based on echocardiography or TR velocity 3.2 m/sec).
- Severe heart failure (NYHA class III or IV or LVEF < 45%).
- Six-minute walk distance < 150 m or > 500 m.
- FEV1/FVC ratio < 0.7 at screening (post-bronchodilator).
- Residual volume > 100% predicted.
- Any condition other than IPF likely to result in the death of the participant within the next two years.
- History of unstable or deteriorating cardiac or neurologic disease.
- Pregnancy or lactation. Patients who are: (a) pregnant or (b) breast feeding are excluded from the study.
- Current treatment with corticosteroids (either oral or inhaled), Cytoxan, azathioprine, colchicine, pirfenidone, anti-tumor necrosis factor therapy or endothelin receptor blockers. Prior treatment is permitted, but at least four weeks of treatment washout prior to inclusion in this study are required.
- Investigational therapy for any indication within 28 days prior to enrollment.
- Degenerative arthritis, cerebrovascular accident or other limitation to mobility preventing completion of the 6-minute walk test.
- Oxygen saturation on room air <80% at rest.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01118221
United States, Florida | |
VA Medical Center, Miami | |
Miami, Florida, United States, 33125 |
Principal Investigator: | Robert M Jackson, MD | VA Medical Center, Miami |
Publications of Results:
Responsible Party: | VA Office of Research and Development |
ClinicalTrials.gov Identifier: | NCT01118221 History of Changes |
Other Study ID Numbers: |
O7467-R |
First Posted: | May 6, 2010 Key Record Dates |
Results First Posted: | January 16, 2015 |
Last Update Posted: | March 4, 2015 |
Last Verified: | February 2015 |
Keywords provided by VA Office of Research and Development:
oxidant stress exercise |
Additional relevant MeSH terms:
Fibrosis Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Idiopathic Interstitial Pneumonias |
Pathologic Processes Lung Diseases Respiratory Tract Diseases Lung Diseases, Interstitial |